Fecal microbiota transplantation (FMT) represents a new therapeutic option that has been studied in two randomized-controlled trials in ulcerative colitis patients.
Dr Jonas Zeitz and colleagues identified patients’ views on the use of this novel therapeutic approach.
Using an anonymous questionnaire, the team obtained data from 574 inflammatory bowel disease (IBD) patients on their knowledge and willingness to undergo FMT.
A large proportion of IBD patients are unaware that fecal microbiota transplantation is a therapeutic option in Clostridium difficile infection and potentially IBD.
The research team, found that more responders preferred fecal microbiota transplantation to a study with a new medication, although the difference was not significant, and the preferred way of transplantation was colonoscopy.
In all, the research team found that 8% preferred a family member as a donor, but there was fear about the procedure.
The knowledge of successful FMT treatment in other patients was important for 82% of responders, and for 51%, a discussion with a specialist would likely change their opinion about fecal microbiota transplantation.
Dr Zeitz's team concluded, "Fecal microbiota transplantation represents a therapeutic procedure that is of interest for IBD patients."
"As fecal microbiota transplantation has been receiving increasing interest as an alternative treatment in IBD and more studies on fecal microbiota transplantation in IBD are being carried out, it is important to learn about the knowledge, attitude, and preferences of patients to provide better education to patients on this topic."
"However, there are reservations because of the fact that data on the benefits of fecal microbiota transplantation in IBD are controversial and several limitations exist on the use of Fecal microbiota transplantation in IBD."